Objectives
To correlate the characteristics and clinical course in pregnant women with severe and non‐severe infection by SARS‐CoV2 in General Hospital of Mexico.
Methods
Observational and descriptive study of clinical features, laboratory and cabinet studies of pregnant with SARS‐CoV2 who requested obstetric care at the General Hospital of Mexico, from April to May 2020. It was used to graph graphpad prism 8.
Results
In General Hospital of Mexico April‐May 2020, 16 patients confirmed for SARS‐CoV2 by rt‐PCR.
Symptoms: cough 13/16 (81.2%), fever, myalgia or arthralgia and dyspnea 9/16 (56.2%), pharyngodynia 7/16 (43.7%), fatigue 6/16 (37.5%).
Morbidities: obesity 6/16 (37.5%), gestational diabetes 4/16 (25%), no morbidity 4/16 (25%), gestational hypertension 2/16 (12.5%).
Chest x‐ray: polished glass 9/16 (56.2%), parenchymal consolidation 7/16 (43.7%) and 7/16 (43.7%) no radiography was performed. Chest tomography 3/16 parenchymal consolidation and polished glass. Severe infection 2/16 (12.5%) and non‐severe infection 9/16 (56.2%), and a subgroup of patients who required ambulatory management in 5/16 (31.2%). 2/16 required invasive mechanical ventilation (12.5%), presented sepsis, admission to the intensive care unit. 9/16 (56.2%) without oxygen, 4/16 (25%) nasal tips, 2/16 (12.5%) with invasive mechanical ventilation and 1/16 (6.2%) with a reservoir mask. 3/16 showed clinical improvement during hospitalisation and fetal well‐being corroborated by Doppler flowmetry, with hospital discharge and telephone follow‐up. Caesarean section 6/8 (75%), 2/8 vaginal delivery (25%). In 6/7 Caesarean sections was oligohydramnios.
Neonates 8/8 (100 %) of newborns with rt‐PCR negative for SARS‐VOC‐2 and without reported neonatal mortality.
Conclusions
Pregnant women are among vulnerable groups to complicate before a respiratory infection, therefore it is important to identify clinical characteristics and morbidities that complicate the SARS‐CoV2 infection, which will allow timely diagnosis and multidisciplinary treatment balancing the clinical course of COVID‐19 disease with perinatal results.